Augmentation therapy is the only specific treatment for alpha1-antitrypsin (AAT) deficiency
Intravenous infusion of AAT, also known as augmentation therapy, is the only specific treatment available for AAT deficiency.1
Augmentation therapy has been demonstrated to raise levels of alpha1 antitrypsin in the blood and lungs above the threshold needed to protect lung tissue.2,3
- The goal of augmentation therapy is to correct the deficiency state and keep neutrophil elastase in check2,4
Serum levels of AAT during long-term therapy
The American Thoracic Society/European Respiratory Society guidelines and the COPD Foundation Clinical Practice Guidelines recommend intravenous augmentation therapy for AAT deficiency*,3,5
augmentation picture 2
The evidence for augmentation therapy
The largest and longest cohort of AAT deficiency patients showed that survival was significantly increased with augmentation therapy.6
Cumulative 5-year mortality for patients with baseline FEV1 <50% predicted
Augmentation therapy resulted in a significant reduction in the rate of emphysema progression7
Integrated analysis: emphysema progression for augmentation therapy vs placebo
AAT: alpha1 antitrypsin; CI: confidence interval; COPD: chronic obstructive pulmonary disease; CT: computed tomography; FEV1: forced expiratory volume in 1 second; NHLBI: National Heart, Lung and Blood Institute; PD15: change in 15th percentile of lung density.
*Recommended for individuals with FEV1 35-60% of predicted.